We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass (LEVO-CTS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02025621
First Posted: January 1, 2014
Last Update Posted: November 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Tenax Therapeutics, Inc.
  Purpose
A study to evaluate levosimendan compared with placebo in reducing the composite event rate of all-cause death, perioperative MI, need for new dialysis, or use of mechanical assist (IABP, LVAD or ECMO) in subjects with reduced ejection fraction undergoing cardiac surgery on cardiopulmonary bypass (CPB).

Condition Intervention Phase
Coronary Artery Bypass Grafting Mitral Valve Surgery Low Cardiac Output Syndrome Drug: Levosimendan Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass

Resource links provided by NLM:


Further study details as provided by Tenax Therapeutics, Inc.:

Primary Outcome Measures:
  • Co-primary Efficacy Endpoint [ Time Frame: 30 days ]
    The all-cause death at 30 days or use of mechanical assist device (IABP, LVAD or ECMO) following the start of surgery for poor cardiac function despite inotropic support and adequate fluid replacement) through Day 5

  • Co-primary Efficacy Endpoint [ Time Frame: 30 days ]
    Composite of all-cause death (at 30 days), or perioperative nonfatal MI [CK-MB >10xULN or >100 ng/mL, CK-MB >5xULN or 50 ng/mL with new Q wave (>0.04 seconds wide in two contiguous leads) or new left bundle branch block)] (through Day 5), or need for renal dialysis (through Day 30), or use of mechanical assist device (IABP, LVAD or ECMO) following the start of surgery for poor cardiac function despite inotropic support and adequate fluid replacement) (through Day 5)


Secondary Outcome Measures:
  • Duration of intensive care unit/critical or coronary care unit (ICU/CCU) [ Time Frame: participants will be followed for during the participant's hospital stay up to 30 days ]
    Duration of intensive care unit/critical or coronary care unit (ICU/CCU) length of stay (LOS)

  • Incidence of LCOS defined as cardiac index ≤ 2.0 L/min/m2 for ≥30 minutes despite optimal fluid balance and maximal inotropic support (dobutamine, milrinone, epinephrine, dopamine) [ Time Frame: 5 days ]
    Incidence of LCOS defined as cardiac index ≤ 2.0 L/min/m2 for ≥30 minutes despite optimal fluid balance and maximal inotropic support (dobutamine, milrinone, epinephrine, dopamine), with the fluid balance and maximal inotropic dose at the investigator's discretion)

  • Postoperative use of secondary inotrope (dobutamine, milrinone, epinephrine, dopamine) associated with index surgical procedure [ Time Frame: 5 days ]

Other Outcome Measures:
  • Occurrence of all-cause mortality from randomization through Day 90 [ Time Frame: 90 days ]
  • Postoperative incidence of atrial fibrillation [ Time Frame: 5 days ]
  • Rehospitalization for any cause through Day 30 [ Time Frame: 30 days ]

Enrollment: 880
Study Start Date: July 2014
Study Completion Date: November 2016
Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Levosimendan
levosimendan 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
Drug: Levosimendan
Other Name: Simdax
Placebo Comparator: Placebo
placebo 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
Drug: Placebo
matching placebo

Detailed Description:
This study is being done to evaluate the efficacy of levosimendan compared with placebo in reducing the co-primary endpoints of 30-day composite of all-cause death or use of mechanical assist device (IABP, LVAD or ECMO) or the composite event rate of all-cause death, perioperative MI, need for dialysis, or use of mechanical assist (IABP, LVAD or ECMO) in subjects with reduced ejection fraction undergoing cardiac surgery on CPB.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented LVEF ≤35% measured by ventriculogram, echocardiogram (ECHO), nuclear scan, or MRI within 60 days before surgery.
  • Scheduled or urgent 1) CABG surgery, 2)CABG with aortic valve surgery, 3) CABG with mitral valve surgery, or 4) mitral valve surgery with or without other valves
  • Surgery will employ CPB pump
  • Signed (by the subjects or their legally acceptable representatives) informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion Criteria:

  • Restrictive or obstructive cardiomyopathy, constrictive pericarditis, restrictive pericarditis, pericardial tamponade, or other conditions in which cardiac output is dependent on venous return.
  • Evidence of systemic bacterial, systemic fungal, or viral infection within 72 hours before surgery.
  • Dialysis at randomization (either hemodialysis, peritoneal dialysis, continuous venovenous hemofiltration, or ultrafilitration).
  • Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2.
  • Weight ≥ 170 kg.
  • Patients whose SBP cannot be managed to ensure SBP > 90 mmHg at initiation of study drug.
  • Heart rate ≥ 120 bpm, persistent for at least 10 minutes screening and unresponsive to treatment.
  • Hemoglobin < 80 g/L.
  • Serum potassium < 3.5 mmol/L and > 5.5 mmol/L at baseline.
  • A history of Torsades de Pointes.
  • Mechanical assist device (IABP, LVAD, ECMO) in the patient at the start of surgery or pre-planned to be inserted during surgery before coming off CPB.
  • Patients with aortal femoral occlusive disease that would prohibit use of IABP unless VAD or ECMO not available.
  • Liver dysfunction Child Pugh Class B or C
  • Patients having severely compromised immune function
  • Pregnant, suspected to be pregnant, or breast-feeding.
  • Received an experimental drug or used an experimental medical device in previous 30 days.
  • Known allergic reaction or sensitivity to Levosimendan or excipients.
  • Received commercial Levosimendan within 30 days before the planned start of study drug.
  • Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02025621


  Hide Study Locations
Locations
United States, Alabama
University of Alabama at Burlington Hospital
Burlington, Alabama, United States
Huntsville Hospital
Huntsville, Alabama, United States
United States, California
Mercy General Hospital
Sacramento, California, United States
University of California San Diego Medical Center
San Diego, California, United States
Stanford University School of Medicine
Stanford, California, United States
United States, Connecticut
Hartford Hospital
Hartford, Connecticut, United States
Yale-New Haven Hospital
New Haven, Connecticut, United States
United States, Florida
Boca Raton Community Hospital
Boca Raton, Florida, United States
Shands Hospital at the University of Florida
Gainesville, Florida, United States
Tampa General Hospital
Tampa, Florida, United States
United States, Georgia
Redmond Regional Medical Center
Rome, Georgia, United States
United States, Illinois
Northwestern University Hospital
Evanston, Illinois, United States
United States, Indiana
Lutheran Hospital of Indiana
Ft. Wayne, Indiana, United States
Franciscan St. Francis Health
Indianapolis, Indiana, United States
United States, Iowa
Iowa Heart Center/ Mercy Medical Center
West Des Moines, Iowa, United States
United States, Kentucky
University of Louisville Hospital
Lousiville, Kentucky, United States
United States, Maine
Maine Medical Center
Portland, Maine, United States
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States
Tufts Medical Center
Boston, Massachusetts, United States
United States, Michigan
St. Joseph's Mercy Hospital
Ann Arbor, Michigan, United States
Oakwood Hospital and Medical Center
Dearborn, Michigan, United States
Spectrum Health
Grand Rapids, Michigan, United States
United States, Missouri
St. Luke's Hospital
Kansas City, Missouri, United States
Barnes Jewish Hospital
St. Louis, Missouri, United States
United States, Nebraska
Nebraska Heart Institute
Lincoln, Nebraska, United States
Nebraska Medical Center
Omaha, Nebraska, United States
United States, New Jersey
Morristown Medical Center
Morristown, New Jersey, United States
United States, New York
St. Peter's Hospital
Albany, New York, United States
Columbia University Medical Center
New York, New York, United States
Lenox Hill Hospital
New York, New York, United States
Mount Sinai Medical Center
New York, New York, United States
Saint Francis Hospital/The Heart Center
Roslyn, New York, United States
United States, North Carolina
Mission Hospital
Asheville, North Carolina, United States
Moses H. Cone Memorial Hospital
Greensboro, North Carolina, United States
Duke University Hospital
Raleigh, North Carolina, United States
United States, Ohio
The Christ's Hospital; Lindner Clinical Trial Center
Cincinnati, Ohio, United States
Case Medical Center
Cleveland, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
Ohio State University Hospital
Columbus, Ohio, United States
ProMedica Toledo Hospital
Toledo, Ohio, United States
United States, Oklahoma
Oklahoma Heart Hospital
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Lehigh Valley Hospital
Allentown, Pennsylvania, United States
United States, Tennessee
St. Thomas Heart
Nashville, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
United States, Texas
Baylor Hospital
Dallas, Texas, United States
The Heart Hospital Baylor Plano
Plano, Texas, United States
United States, Virginia
University of Virginia Health System
Charlottesville, Virginia, United States
United States, Washington
Franciscan Health System Res. Center
Tacoma, Washington, United States
United States, Wisconsin
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, United States
Canada, Alberta
University of Alberta Hospital
Edmonton, Alberta, Canada
Canada, British Columbia
Royal Jubilee Hospital (Vancouver Island Health Authority)
Victoria, British Columbia, Canada
Victoria Heart Institute Foundation
Victoria, British Columbia, Canada
Canada, Manitoba
St. Boniface Hospital
Winnepeg, Manitoba, Canada
Canada, Ontario
Hamilton Health Sciences
Hamilton, Ontario, Canada
London Health Sciences Center, University Hospital
London, Ontario, Canada
Southlake Regional Health Center
Newmarket, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Canada, Quebec
McGill University Health Centre-Royal Victoria Hospital
Montreal, Quebec, Canada
Montreal Heart Institute
Montreal, Quebec, Canada
Canada
Institute universitaire de cardiologie et pneumologie de Quebec
Quebec, Canada
Sponsors and Collaborators
Tenax Therapeutics, Inc.
Investigators
Principal Investigator: Rajendra Mehta, MD Duke Clinical Research Institute
Study Chair: John Alexander, MD Duke Clinical Research Institute
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Tenax Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02025621     History of Changes
Other Study ID Numbers: TNX-LVO-01
First Submitted: December 18, 2013
First Posted: January 1, 2014
Last Update Posted: November 6, 2017
Last Verified: November 2016

Keywords provided by Tenax Therapeutics, Inc.:
coronary artery bypass grafting
CABG
mitral valve
LCOS
low cardiac output syndrome
levosimendan

Additional relevant MeSH terms:
Ventricular Dysfunction, Left
Cardiac Output, Low
Ventricular Dysfunction
Heart Diseases
Cardiovascular Diseases
Signs and Symptoms
Simendan
Anti-Arrhythmia Agents
Cardiotonic Agents
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Protective Agents
Physiological Effects of Drugs